935106861
info@markelab.com
Precio
375€ (100 µg)
Bemarituzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting FGFR2, Bemarituzumab is a subtype-selective humanized monoclonal antibody against FGFR2b. The FIGH study aims to evaluate the efficacy of its combined chemotherapy for untreated advanced gastric cancer or gastroesophageal junction cancer.
Biosimilars
Human
Monoclonal
Human
FGFR2
Human
IgG1 Kappa
Unconjugated
Liquid
ELISA, WB
100 µg
1 mg
Recombinant
> 95%
Purified from cell culture supernatants by Protein A/G chromatography.
0.01 M PBS. pH 7.4.
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
No
Shipped within 7-12 working days.
Biosimilars
CAS Number 1952272-74-0
Precio a consultar
Ver másPrecio a consultar
Ver másPrecio a consultar
Ver más